Biotech Sector Analysis: March Madness
Source: John McCamant, Medical Technology Stock Letter  (3/15/13)
"Sound sector and company fundamentals are intact, and improving in some cases. The industry gatekeeper—the U.S. Food and Drug Administration (FDA)—continues to be cooperative. The bullish stock market also bodes well—as cash flows into healthcare funds remain abundant—driving many stocks to what appear to be extended levels." More >

This Healthcare Fund Is Up 70%: Why I'm Not Selling
Source: Steve Sjuggerud, Steve Sjuggerud's Daily Wealth  (3/12/13)
"Have your exit plan in place, but don't sell. As I've explained many times, this market has the potential to run much higher." More >

What Will Boost Medtech Stocks? Look for a Better Mousetrap, Says William Plovanic
Source: George S. Mack of The Life Sciences Report  (2/21/13)
Growth in the medical technology industry may have slowed, and governmental hurdles may make the forecast gloomy, but value plays await the investor who understands how innovation can drive company stock prices upward. In this interview with The Life Sciences Report, William Plovanic, analyst and managing director with Canaccord Genuity, talks about his top names in medtech and why he believes investors need to take advantage of the slowdown now. He also ruminates on the potential effects of Obamacare's impending implementation. More >

Analysts' Watchlist 2013
Source: George S. Mack of The Life Sciences Report  (1/31/13)
More >

The Life Sciences Report Watchlist 2013
Source: George S. Mack of The Life Sciences Report   (1/31/13)
Which biotech companies will take off in 2013? To zero in on possible winners, The Life Sciences Report teamed up with Sagient Research to crunch the numbers for companies with potential catalysts on the calendar. The results were sent to experts who, based on their experience in the space, could determine which companies have the best chances for upward stock price movement. The result is the groundbreaking Life Sciences Report Watchlist 2013. In this exclusive article, you can follow the thought process that went into generating the short list, and learn more about the potential winners and what they are poised to accomplish in the next 12 months. More >

The Pulse: Breaking News from the Life Sciences Sector
Source: Editors of The Life Sciences Report  (1/7/13)
To invest wisely in the life sciences, broad-spectrum knowledge is key. Such knowledge encompasses not only the analysis of industry experts featured in Streetwise Reports interviews, but also up-to-date news on cutting-edge research and development, the latest mergers and acquisitions and the drug development process, both within companies and in the regulatory arena. Our Twitter feed links you to the information you need to profit, both intellectually and financially. More >

This Alzheimer's "Pacemaker" Could Be the Bridge to a Cure
Source: Michael Robinson, Money Morning  (1/2/13)
"As high-tech investors, we need to keep an eye on this research and be ready to pounce when a medical device maker gets it to market." More >

2012: A Healthy Year for the Life Sciences
Source: Editors of The Life Sciences Report  (12/27/12)
What is the value of innovation? Of addressing unmet needs? Of new and "disruptive" technologies? Those are just a few of the issues that industry experts tackled in interviews with The Life Sciences Report during 2012. Among the many therapeutic focuses discussed by analysts over the last year, orphan diseases and hepatitis C were identified early on as market "sweet spots." Oncology was another big hitter: From micro caps to big pharma, companies targeted the "emperor of all maladies" with innovative pharmaceuticals and genetic technologies. And analysts also uncovered the unexpected, including a pharmaceuticalized nutraceutical designed to reduce high cholesterol. More >

Top 20 Venture Capital Firms
Source: Genetic Engineering and Biotechnology News  (12/18/12)
"Venture capital firms, in exchange for equity in the companies in which they’re investing, can help provide funds for companies they think have high potential. So, which VC firms have helped pump up the most biotech and biopharma companies?" More >

Cliff Spells Danger for Biotechs
Source: Alex Philippidis, Genetic Engineering and Biotechnology News  (12/12/12)
"If Obama and Congress cannot agree, key agencies face cuts while tax changes would dampen new investment." More >

Breakthrough Technologies Target Disease Diagnosis, the Blind and the Brain
Source: Michael Robinson, Money Morning  (12/3/12)
"With optogenetics, researchers select cells in the brain they want to make sensitive to a particular light color. Then they use the light to tell precise regions of the brain to activate or not." More >

'Pipeline' Device Offers New Option for Difficult-to-Treat Brain Aneurysms
Source: Science Daily  (12/3/12)
"The study reflects the increased emphasis on collecting post-marketing data on newly approved medical devices to see if the results in initial clinical experience are comparable to those in research trials." More >

Personalized Diagnostic Medicine Coming of Age
Source: George S. Mack of The Life Sciences Report  (11/29/12)
As little as a decade ago we were all thinking in terms of one blood draw being the be-all and end-all of diagnostics. With the first human genome sequenced, it would only require a panel of genetic, epigenetic, proteomic and small molecule metabolic markers. That was all we needed, we thought. Today it's clear that we got ahead of ourselves. Yes, the search is still on for the right biomarkers, but it’s going to be more about organizing the data and tying it together with history of present and past illness to render more definitive diagnostics. I spoke with Ladenburg Thalmann & Co. Director of Health Care Research Kevin DeGeeter about this very topic. More >

This 'Segway with Legs' Is Nothing Short of A Miracle
Source: Michael Robinson, Money Morning  (11/11/12)
"It's hard to say what the market could be worth, but Thomson Reuters reported that ABI Research forecast a market of $320M for bionic exoskeletons within 10 years." More >

Analyst Scott Power Finds the Upside in Biotech Down Under
Source: George S. Mack of The Life Sciences Report  (11/8/12)
If you're looking for fresh international names in biotech and medtech, but need the comforts of end markets on U.S. soil, the best ideas of RBS Morgans Ltd. Senior Analyst Scott Power might be for you. In this interview with The Life Sciences Report, Australia-based Power makes a case for important life science names with Australian origins and a U.S. presence that could present investors with huge upside. More >

Election Roundup: News from the Healthcare Front
Source: Tracy Salcedo-Chourre of The Life Sciences Report  (11/8/12)
With the reelection of President Barack Obama, the biggest reforms to hit healthcare in nearly a century are positioned to come online. Some provisions of the Patient Protection and Affordable Care Act (aka Obamacare) have already taken effect, but those remaining are likely to have significant impacts on the business of life science. Whether the reforms bode good or ill for biotech and medtech investors has yet to be seen. We've provided a few beats of the media and blog pulse below, and will keep you informed as developments unfold. More >

10 Top Women in Biotech 2012
Source: Fierce Biotech  (11/8/12)
"Too few female professionals rise to senior executive roles in the biopharma industry, making the accomplishments of these women all the more exceptional." More >

A Capital-Efficient Prescription for New Drugs: Raghuram "Ram" Selvaraju
Source: George S. Mack of The Life Sciences Report   (11/1/12)
The small biotech companies that have survived the last five years have learned to be lean, mean and efficient with shareholder capital. In this exclusive interview with The Life Sciences Report, Aegis Capital's Managing Director and Head of Equity Research Raghuram "Ram" Selvaraju discusses companies that have mitigated risk by giving new life and higher margins to products previously relegated to the dustbin of commoditized generics. He also highlights some very new and exciting developments in the realm of stem cell technologies and monoclonal antibodies that engage never-before-targeted molecules. More >

Our Next President and Healthcare Policy
Source: BioSpace, Karl Thiel  (10/30/12)
"Both candidates paint this as a vitally important election between leaders with starkly different views of policy and governing. So if the fate of the life sciences potentially hangs in the balance, what are we likely to see in the months ahead?" More >

Q3 Biotech Venture Investing Makes a Boisterous Leap
Source: FierceBiotech, John Carroll  (10/19/12)
"Using the figures provided by Thomson Reuters, the quarterly report concluded that total life sciences venture deals topped $1.7B in 181 deals in the third quarter—a bit more than a quarter of all investments tracked during the period." More >

What Moves Biotech Stocks? Ed Arce Has Answers.
Source: George S. Mack of The Life Sciences Report   (10/18/12)
Biotech stocks move on material news, which means clinical data, regulatory progress, new partnerships and big contracts with new customers. Analyst Ed Arce of MLV & Co. holds to these principles as he shares compelling biotech names in this exclusive interview with The Life Sciences Report. More >

Is Medical Device Tax a Lame Duck?
Source: Mass Device   (10/12/12)
"There's a growing confidence among medical device industry insiders that there may be an opportunity to repeal the medical device tax in the interim session between the November election and the seating of a new Congress—no matter who wins the race to the White House." More >

Casey Analyst Forecasts Explosive Biotech Growth
Source: Streetwise Staff  (10/11/12)
The myth of technology, whether for smartphones or cancer treatments, is that the next big thing appears suddenly and magically. Casey Research Analyst Alex Daley sets the record straight in this exclusive interview with The Life Sciences Report. While the science of genetic medicine has accelerated the process of turning magical thinking into practical medicine, Daley cautions investors in biotech and medical device companies to be patient, and names companies with innovative technologies poised for explosive growth. More >

Much-Hyped Renal Denervation Devices Could Help Diabetics, Too
Source: Fierce Medical Devices, Damian Garde  (10/5/12)
"Renal denervation devices, designed to treat hypertension, are already tabbed for big sales in that sphere--$2.8 billion by 2020, analysts say. Now, new research suggests the nerve-deadening procedure could benefit diabetics, an even larger patient population." More >

Medtech Industry Stock Outlook: October 2012
Source: Zacks Equity Research  (10/2/12)
"Several catalysts for growth exist, including new product cycles, an aging population, geographic expansion, ongoing transition toward minimally invasive techniques and emerging markets." More >